Exploring CAR-T cell therapy in AML treatment has unveiled new targets, notably leukocyte immunoglobulin-like receptor B4 (LILRB4) and Sialic acid-binding Ig-like lectin 6 (Siglec-6). The gene discussed is LILRB4; the disease is acute myeloid leukemia.